Pfizer is pausing large-scale acquisitions to prioritize operational transformation through artificial intelligence. This shift follows the $43 billion purchase of oncology specialist Seagen in 2023. The company previously used aggressive deal-making to mitigate upcoming patent expirations on key drugs.
The AI initiative aims to streamline processes, reduce costs, and improve overall efficiency. Management expects these internal improvements to drive stronger earnings and sustainable long-term growth. This strategy seeks to reverse a significant five-year decline in Pfizer’s stock price.
Analysts suggest the strategic pivot could benefit long-term investors. Pfizer currently offers a high dividend yield and a low stock valuation. AI-led efficiencies may further enhance the company's investment appeal.